Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 15/20 | 1.00 |
| ▸ | SLC5A2 | P31639 | 13/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30268946 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL7581216 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL14104531 | 1.00 | SLC5A1 (1.00) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL14080086 | 0.94 | SLC5A1 (0.89) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL16854936 | 0.93 | SLC5A1 (0.86) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL12808039 | 0.93 | SLC5A1 (0.86) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL13046266 | 0.91 | SLC5A1 (0.84) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL12922941 | 0.91 | SLC5A1 (0.84) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL7582187 | 0.91 | SLC5A1 (0.83) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 | |
| SCHEMBL7591628 | 0.91 | SLC5A1 (0.83) | SLC5A1SLC5A2HPGDHSD17B10SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278268-B2 | administering peroxisome proliferator-activated receptor agonists (PPAR) and sodium glucose co-transporters (SGLTs) inhibitors for the treatment of diabetes and Syndrome X | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278268-B2 | administering peroxisome proliferator-activated receptor agonists (PPAR) and sodium glucose co-transporters (SGLTs) inhibitors for the treatment of diabetes and Syndrome X | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8183213-B2 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183213-B2 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-1392326-B1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL JANSSEN PHARM (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2065044-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | BUSSOLARI JACQUELINE C | 2009-03-19 | — | — | US | disclosed |
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | BUSSOLARI JACQUELINE C | 2009-03-19 | — | — | US | disclosed |
| US-20080096802-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS | BUSSOLARI JACQUELINE C | 2008-04-24 | — | — | US | disclosed |
| US-20080096802-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS | BUSSOLARI JACQUELINE C | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | GPR119, SLC2A4, SLC2A1 | SLC5A1 10/4885SLC5A2 12/4885HPGD 1034/4885 |
| US-20080096802-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS | GPR119, SLC2A4, PPARG | SLC5A1 6/4885SLC5A2 10/4885HPGD 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.